Seminars in Hematology
Volume 43 , Pages S3-S9 , January 2006

Impact of Choice of Treatment for Bleeding Episodes on Inhibitor Outcome in Patients With Mild/Moderate Hemophilia A and Inhibitors

  • Roseline d’Oiron

      Affiliations

    • Hemophilia Center, APHP Bicêtre University Hospital, Le Kremlin-Bicêtre, France
    • Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
    • Corresponding Author InformationAddress correspondence to Roseline d’Oiron, MD, Hemophilia Center, Hôpital Bicêtre, 78 avenue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex, France.
    • ,
  • F. Volot

      Affiliations

    • Hemophilia Centers—University Hospital of Dijon (France)
    • ,
  • J. Reynaud

      Affiliations

    • Hemophilia Centers—University Hospital of St-Etienne (France)
    • ,
  • K. Peerlinck

      Affiliations

    • Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
    • ,
  • J. Goudemand

      Affiliations

    • Hemophilia Centers—University Hospital of Lille (France)
    • ,
  • C. Guérois

      Affiliations

    • Hemophilia Centers—University Hospital of Tours (France)
    • ,
  • C. Rothschild

      Affiliations

    • Hemophilia Centers—University Hospital of Paris Necker (France)
    • ,
  • H. Chambost

      Affiliations

    • Hemophilia Centers—University Hospital of Marseille (France)
    • ,
  • A. Borel-Derlon

      Affiliations

    • Hemophilia Centers—University Hospital of Caen (France)
    • ,
  • V. Roussel-Robert

      Affiliations

    • Hemophilia Centers—University Hospital of Paris Cochin (France)
    • ,
  • A. Marquès-Verdier

      Affiliations

    • Hemophilia Centers—University Hospital of Clermont-Ferrand (France)
    • ,
  • A. Lienhart

      Affiliations

    • Hemophilia Centers—University Hospital of Lyon (France)
    • ,
  • A.M. Berthier

      Affiliations

    • Hemophilia Centers—University Hospital of Rennes (France)
    • ,
  • P. Moreau

      Affiliations

    • Hemophilia Centers—University Hospital of Le Mans (France)
    • ,
  • T. Lambert

      Affiliations

    • Hemophilia Center, APHP Bicêtre University Hospital, Le Kremlin-Bicêtre, France
    • ,
  • MHAI Study Group

References 

  1. Beck P , Giddings JC , Bloom AL . Inhibitor of factor VIII in mild hemophilia . Br J Haematol . 1969;17:283–288
  2. Hay CRM , Ludlam CA , Colvin BT , Hill FGH , Preston FE , Wasseem N , et al.  Factor VIII inhibitors in mild and moderate-severity haemophilia A . Thromb Haemost . 1998;79:762–766
  3. Ören H , Yaprak I , Irken G . Factor VIII inhibitors in patients with hemophilia A . Acta Haematol . 1999;102:42–46
  4. Colvin BT , Hay CRM , Hill FG , Preston FE . The incidence of factor VIII inhibitors in the United Kingdom, 1990-93 . Br J Haematol . 1995;89:908–910
  5. Ehrenforth S , Kreuz W , Scharrer I , Linde R , Funk M , Gungor T , et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs . Lancet . 1992;339:594–598
  6. Oldenburg J , El-Maarri O , Schwaab R . Inhibitor development in correlation to factor VIII genotypes . Haemophilia . 2002;8:23–29
  7. Lusher JM , Arkin S , Abildgaard CF , Schwartz RS  Kogenate Previously Untreated Patient Study Group . Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors . N Engl J Med . 1993;328:453–459
  8. Sharathkumar A , Lillicrap D , Blanchette VS , Kern M , Leggo J , Stain AM , et al.  Intensive exposure to factor VIII is a risk for inhibitor development in mild hemophilia A . J Thromb Haemost . 2003;1:1228–1236
  9. Bauduer F , Ducout L , Bendriss P , Falaises B , Lavergne JM . Mild haemophilia A discovered in a previously multi-operated 73-year-old man (Characterization of a new mutation) . Haemophilia . 2001;7:419–421
  10. Bovill EG , Burns SL , Golden EA . Factor VIII antibody in a patient with mild haemophilia . Br J Haematol . 1985;61:323–328
  11. Capel P , Toppet M , van Remoortel E , Fondu P . Factor VIII inhibitor in mild haemophilia . Br J Haematol . 1986;62:786–787
  12. Crowell EB . A factor VIII inhibitor in a mild hemophiliac . Am J Med Sci . 1970;260:261–263
  13. Fijnvandraat K , Turenhout EAM , van den Brink EN , ten Cate JW , van Mourik JA , Peters M , et al.  The missense mutation Arg593→Cys is related to antibody formation in a patient with mild hemophilia A . Blood . 1997;89:4371–4377
  14. Kesteven PJ , Holland LJ , Lawrie AS , Savidge GF . Inhibitor to factor VIII in mild haemophilia . Thromb Haemost . 1984;52:50–52
  15. Knobe KE , Villoutreix BO , Tengborn LI , Petrini P , Ljung RC . Factor VIII inhibitors in two families with mild haemophilia A (Structural analysis of the mutations) . Haemostasis . 2000;30:268–279
  16. Leebeek FWG , Kappers-Klunne MC , Jie KSG . Effective and safe use of recombinant factor VIIa (NovoSeven®) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII . Haemophilia . 2004;10:250–253
  17. Lechner K , Ludwig E , Niessner H , Thaler E . Factor VIII inhibitor in a patient with mild hemophilia A . Hemostasis . 1972;1:261–270
  18. Liu ML , Nakaya S , Thompson AR . Non-inversion factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses . Thromb Haemost . 2002;87:273–276
  19. Lowe G , Forbes CD . Inhibitor to factor VIII in mild haemophilia . Thromb Haemost . 1985;53:159
  20. Peerlinck K , Arnout J , Jacquemin M , Gilles JG , Lavend’homme R , Kreson K , et al.  A patient with mild hemophilia and a high titer antifactor VIII antibody against exogenous factor VIII only (Clinical features, surgical management and partial characterization of the inhibitor) . Blood . 1997;90(suppl 1):36a
  21. Peerlinck K , Jacquemin MG , Arnout J , Hoylaerts MF , Gilles JGG , Lavend’homme R , et al.  Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A . Blood . 1999;93:2267–2273
  22. Puetz JJ , Bouhasin JD . High-titre factor VIII inhibitor in two children with mild haemophilia A . Haemophilia . 2001;7:215–219
  23. Robbins D , Kulkarni R , Gera R , Scott-Emuakpor AB , Bosma K , Penner JA . Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy . Am J Hematol . 2001;68:184–188
  24. Roussel-Robert V , Torchet MF , Legrand F , Rothschild C , Stieltjes N . Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients . J Thromb Haemost . 2003;1:2450–2541
  25. Santagostino E , Gringeri A , Tagliavacca L , Mannucci PM . Inhibitors to factor VIII in a family with mild hemophilia (molecular characterization and response to factor VIII and desmopressin) . Thromb Haemost . 1995;74:619–621
  26. Suzuki T , Arai M , Miyasaka S , Watanabe J , Sugimura D , Amano K , et al.  Factor VIII inhibitor developed in a 60-year-old patient with mild hemophilia A after surgery for colon cancer . Int J Hematol . 1995;62:127–132
  27. Thompson AR , Murphy MEP , Liu ML , Saenko EL , Healey JF , Lollar P , et al.  Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation . Blood . 1997;90:1902–1910
  28. Yee TT , Pasi KJ , Lilley PA , Lee CA . Factor VIII inhibitors in haemophiliacs (A single-centre experience over 34 years, 1964-97) . Br J Haematol . 1999;104:909–914
  29. White B , Cotter M , Byrne M , O’Shea E , Smith OP . High responding factor VIII inhibitors in mild haemophilia—Is there a link with recent changes in clinical practice? . Haemophilia . 2000;6:113–115
  30. van den Brink EN , Timmermans SM , Turenhout EA , Bank CM , Fijnvandraat K , Voorberg J , et al.  Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593→Cys substitution . Thromb Haemost . 1999;81:723–726
  31. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, on behalf of the Factor VIII and Factor IX Subcommittee: Classification of inhibitors. Scientific Subcommittees on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Minutes and Annual report 2000, http://www.med.unc.edu/isth/SSC/communications/factor8and9/defhem.pdf
  32. Gill J: Proposal to refine the low response inhibitor definition. Scientific Subcommittees on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Minutes and Annual report 2004, http://www.med.unc.edu/isth
  33. Oldenburg J , Schroder J , Hermann Brackmann H , Muller-Reible C , Schwaab R , Tuddenham E . Environmental and genetic factors influencing inhibitor development . Semin Hematol . 2004;41(suppl 1):82–88
  34. Kemball-Cook G , Tuddenham EG , Wacey AI . The factor VIII structure and mutation resource site (HAMSTeRS version 4) . Nucleic Acids Res . 1998;26:216–219
  35. Jacquemin M , Benhida A , Peerlinck K , Desqueper B , Vander Elst L , Lavend’homme R , et al.  A human antibody directed to the factor VIII domain inhibits factor VIII cofactor activity and binding to von Willebrand factor . Blood . 2000;95:156–163
  36. Jacquemin M , Lavend’homme R , Benhida A , Vanzieleghem B , d’Oiron R , Lavergne JM , et al.  A novel cause of mild/moderate hemophilia A (mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor) . Blood . 2000;96:958–965
  37. Bril WS , Turenhout EAM , Kaijen PHP , van den Brink EN , Koopman MMW , Peters M , et al.  Analysis of factor VIII inhibitors in a haemophilia A patient with an Arg593→Cys mutation using phage display . Br J Haematol . 2002;119:393–396
  38. Bril WS , MacLean PE , Kaijen PHP , van den Brink EN , Lardy NM , Fijnvandraat K , et al.  HLA class II genotype and factor VIII inhibitors in mild hemophilia A patients with an Arg593 to Cys mutation . Haemophilia . 2004;10:509–514
  39. Hay CR , Ollier W , Pepper L , Cumming A , Keeney S , Goodeve AC , et al.  HLA class II profile (A weak determinant of factor VIII inhibitor development in severe hemophilia A) . Thromb Haemost . 1997;77:234–237
  40. Oldenburg J , Picard JK , Schwaab R , Brackmann HH , Tuddenham EG , Simpson E . HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII . Thromb Haemost . 1997;77:238–242
  41. Astermark J , Berntorp E , White GC , Kroner BL  The MIBS Study Group . The Malmö International Brother Study (MIBS) (Further support for genetic predisposition to inhibitor development) . Haemophilia . 2001;7:267–272
  42. Vlot AJ , Wittebol S , Strengers PF , Turenhout EA , Voorberg J , van den Berg HM , et al.  Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618→Ser mutation responsive to immune tolerance induction and cyclophosphamide . Br J Haematol . 2002;117:136–140
  43. Wiestner A , Cho HJ , Asch AS , Michells MA , Zeller JA , Peerschke EIB . Rituximab in the treatment of acquired factor VIII inhibitors . Blood . 2002;100:3426–3428
  44. Johannessen M , Andreasen RB , Nordfang O . Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven . Blood Coagul Fibrinolysis . 2000;11:239–242
  45. Karayalcin G , Goldberg B , Cherrick I , Kurer C , Bierman F , Lanzkowsky P . Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8-year-old boy with hemophilia A and factor VIII inhibitor . Am J Pediatr Hematol Oncol . 1993;15:416–419

 See Appendix for list of MHAI Study Group investigators.

PII: S0037-1963(05)00209-X

doi: 10.1053/j.seminhematol.2005.11.002

Seminars in Hematology
Volume 43 , Pages S3-S9 , January 2006

Article Tools